0.7901
price up icon5.35%   0.0401
 
loading
Cue Biopharma Inc stock is traded at $0.7901, with a volume of 201.30K. It is up +5.35% in the last 24 hours and down -35.76% over the past month.
See More
Previous Close:
$0.75
Open:
$0.7341
24h Volume:
201.30K
Relative Volume:
0.83
Market Cap:
$47.51M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.8682
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-20.55%
1M Performance:
-35.76%
6M Performance:
+7.73%
1Y Performance:
-56.59%
1-Day Range:
Value
$0.7341
$0.88
1-Week Range:
Value
$0.7341
$1.05
52-Week Range:
Value
$0.45
$2.26

Cue Biopharma Inc Stock (CUE) Company Profile

Name
Name
Cue Biopharma Inc
Name
Phone
617-949-2680
Name
Address
40 GUEST STREET, BOSTON, MA
Name
Employee
0
Name
Twitter
@cuebiopharma
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
CUE's Discussions on Twitter

Compare CUE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CUE
Cue Biopharma Inc
0.7901 47.51M 9.53M -44.61M -38.32M -0.91
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-24 Initiated Jefferies Buy
Jun-26-23 Resumed Oppenheimer Outperform
Nov-21-22 Initiated Piper Sandler Overweight
Jan-13-22 Initiated H.C. Wainwright Buy
Jan-03-22 Initiated Craig Hallum Buy
Nov-24-20 Initiated Berenberg Buy
Apr-09-20 Initiated Stifel Buy
Jan-28-20 Initiated BTIG Research Buy
Jan-22-20 Initiated JMP Securities Mkt Outperform
View All

Cue Biopharma Inc Stock (CUE) Latest News

pulisher
Apr 02, 2025

Cue Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Cue Biopharma’s Strategic Focus and Financial Outlook - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

What's Going On With Cue Biopharma Shares Tuesday? - Benzinga

Apr 01, 2025
pulisher
Mar 31, 2025

Cue Biopharma earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Yahoo Finance

Mar 31, 2025
pulisher
Mar 24, 2025

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times

Mar 24, 2025
pulisher
Mar 22, 2025

Bleichroeder LP Increases Stake in Cue Biopharma Inc - GuruFocus.com

Mar 22, 2025
pulisher
Mar 21, 2025

[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold

Mar 21, 2025
pulisher
Mar 19, 2025

Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 17, 2025

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Nasdaq

Mar 17, 2025
pulisher
Mar 13, 2025

Cue Biopharma appoints Pasha Sarraf to board By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 12, 2025

Cue Biopharma Appoints Pasha Sarraf to Board - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Cue Biopharma appoints Pasha Sarraf to board - Investing.com

Mar 12, 2025
pulisher
Mar 01, 2025

Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%What's Next? - MarketBeat

Mar 01, 2025
pulisher
Feb 24, 2025

Larger animals really are more prone to cancer, debunking ‘Peto’s paradox’ - Study Finds

Feb 24, 2025
pulisher
Feb 21, 2025

Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace

Feb 21, 2025
pulisher
Feb 20, 2025

HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Feb 20, 2025
pulisher
Feb 17, 2025

Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) - ACCESS Newswire

Feb 17, 2025
pulisher
Feb 12, 2025

Pancreatic Adenocarcinoma Market Growth Projections - openPR

Feb 12, 2025
pulisher
Feb 05, 2025

Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat

Feb 05, 2025
pulisher
Jan 31, 2025

Artiva Biotherapeutics expands board with industry veteran - MSN

Jan 31, 2025
pulisher
Jan 30, 2025

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - The Manila Times

Jan 30, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members - MSN

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com Nigeria

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva expands Board with appointment of Dan Baker, M.D - TipRanks

Jan 29, 2025
pulisher
Jan 29, 2025

Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan

Jan 29, 2025
pulisher
Jan 13, 2025

Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Geode Capital Management LLC Purchases 212,394 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) - Defense World

Jan 13, 2025
pulisher
Jan 06, 2025

HPV16+ Cancer Clinical and Non-Clinical Studies, Key - openPR

Jan 06, 2025
pulisher
Jan 02, 2025

Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World

Jan 02, 2025
pulisher
Dec 27, 2024

The definitive Boston biotech layoff tracker for 2024 - The Business Journals

Dec 27, 2024
pulisher
Dec 25, 2024

Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com

Dec 25, 2024
pulisher
Dec 19, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia

Dec 19, 2024
pulisher
Dec 18, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India

Dec 18, 2024
pulisher
Dec 18, 2024

Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com

Dec 18, 2024
pulisher
Dec 18, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 16, 2024

Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat

Dec 16, 2024
pulisher
Dec 13, 2024

Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com Australia

Dec 13, 2024
pulisher
Nov 29, 2024

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 29, 2024
pulisher
Nov 29, 2024

Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan

Nov 29, 2024
pulisher
Nov 29, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 29, 2024
pulisher
Nov 29, 2024

Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Nov 29, 2024

Cue Biopharma Inc Stock (CUE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):